Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 14;11(2):221. doi: 10.3390/cancers11020221

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Disruption of H2AX interaction with CARP-1 results in enhanced viabilities of CFM-4-, CFM-4.16-, or Adriamycin-treated cells in part due to reduced apoptosis. (A,C,D) Indicated MDA-MB-468 cell lines were treated with DMSO (Control), or with the noted dose and time of Adriamycin, CFM-4, or CFM-4.16 compounds. Determination of viable/live cells was carried out by MTT assay as described in Section 2. (B,E,F) Cell lysates derived from vehicle DMSO (Control), or CFM-4-, CFM-4.16-, or Adriamycin-treated cells were added to the wells that had immobilized fluorogenic substrates of noted caspases. The fluorescence released from the activated caspase-dependent cleavage of respective substrate was detected by a plate reader at the excitation and emission wavelengths of 380 nm and 460 nm, respectively, as detailed in Section 2. The columns in bar charts in panels A, C, D and B, D, F represent means of three and two independent experiments, respectively; bars, SE. For panels C and D, * p < 0.05, **p < 0.01 and *** p ≤ 0.001 relative to the respective EGFP vector subline. For panels E and F, *** p ≤ 0.05 relative to the respective EGFP vector subline.

Disruption of H2AX interaction with CARP-1 results in enhanced viabilities of CFM-4-, CFM-4.16-, or Adriamycin-treated cells in part due to reduced apoptosis. (A,C,D) Indicated MDA-MB-468 cell lines were treated with DMSO (Control), or with the noted dose and time of Adriamycin, CFM-4, or CFM-4.16 compounds. Determination of viable/live cells was carried out by MTT assay as described in Section 2. (B,E,F) Cell lysates derived from vehicle DMSO (Control), or CFM-4-, CFM-4.16-, or Adriamycin-treated cells were added to the wells that had immobilized fluorogenic substrates of noted caspases. The fluorescence released from the activated caspase-dependent cleavage of respective substrate was detected by a plate reader at the excitation and emission wavelengths of 380 nm and 460 nm, respectively, as detailed in Section 2. The columns in bar charts in panels A, C, D and B, D, F represent means of three and two independent experiments, respectively; bars, SE. For panels C and D, * p < 0.05, **p < 0.01 and *** p ≤ 0.001 relative to the respective EGFP vector subline. For panels E and F, *** p ≤ 0.05 relative to the respective EGFP vector subline.